.svg)
.svg)
.svg)
The problem
Tumor associated macrophages (TAMs) are a significant component of all solid tumors and act as a major barrier to T cell recruitment and activation.
TAMs are associated with disease progression, metastasis, and therapy resistance. Our multi-omic analysis defines subsets of TAMs as key drivers of tumor progression and immune suppression across solid tumors.
The solution
Our CAR-engineered monocytes remove specific subsets of TAMs across solid tumors. By eliminating these targets, we enable T cell recruitment, activation and durable responses in solid tumors.
Why KarMac
.svg)
A novel mechanism
CAR-monocytes overcome a fundamental barrier in solid tumors by leveraging the innate tumor-homing properties of monocytes to efficiently infiltrate the tumor microenvironment, enabling effective therapeutic
Designed for solid tumors
Engineered specifically to survive and operate within the hostile microenvironment of solid cancers.
A modular platform
Built on deep myeloid biology, our platform is readily adaptable to target diverse macrophage markers across multiple indications.
Meet the founders
Jennifer Guerriero
.png)
Thomas Marron
.png)
Daniel Michaud
.png)
Alex Gottlieb
Advisory board
Marcela Maus
.png)
Michael Klichinsky
Kristen Hege
